How AOD-9604 Supports Fat Metabolism

What Is AOD 9604? 

AOD 9604 is a synthetic analog of human growth hormone’s (hGH) lipolytic domain. It is hypothesized that it could support weight loss due to its mechanism of action.

How It Works (Mechanism of Action) 

AOD 9604 is the C-terminal fragment belonging to hGH. It is created using solid phase peptide synthesis, which adds an additional tyrosine to the N-terminal. Doing so enables stabilization of the peptide. HGH has several known metabolic functions, including induction of insulin-like growth factor-1 (IGF-1) and lipid and carbohydrate metabolism. Additionally, hGH can inhibit lipoprotein lipase in adipose tissue, causing lipolysis and leading to decreases in fat cell mass (2). 

Although the mechanism of AOD9604 is not well characterized, it has similar biological effects as hGH. Thus, it is postulated it could have some metabolic effects, particularly in the weight loss realm. 

What Does the Research Show? 

AOD 9604 has been evaluated in rodent models of obesity. In one study, obese Zucker rats received daily oral doses of AOD 9604 for 19 days. Results indicated that rats receiving AOD 9604 experienced body weight reductions by greater than 50 percent compared with the control group. Additionally, in the adipose tissues of animals treated with AOD 9604, increased lipolytic activity was noted. Compared to chronic hGH treatment, AOD 9604 demonstrated no negative effects on insulin sensitivity. As such, these findings suggest that AOD 9604 could be a potential therapeutic candidate for obesity (3). 

Another study was conducted similarly in both obese and lean mice. Mice were treated with hGH, AOD 9604, or saline for a period of 14 days. Both AOD 9604 and hGH caused significant decreases in body weight in obese mice. This was due to increased plasma glycerol levels (which is an indicator of lipolysis) and in vivo fat oxidation. AOD 9604 differed from hGH in that it did not lower insulin secretion or cause hyperglycemia (4). 

A few studies in humans have been performed with AOD 9604. In these studies, AOD 9604 was generally safe and well tolerated. However, although weight loss was observed in some studies, it did not occur in all studies (2). 

Clinical Relevance (Real-World Perspective) 

Animal studies are suggestive of a potential of AOD 9604 in supporting weight loss. Although a few studies have been conducted in humans, the results are mixed and ultimately the drug is not approved by the US Food and Drug Administration (FDA). 

Safety, Regulation, and Quality Concerns 

From a regulatory perspective, AOD 9604 is not approved by the US FDA, and thus it has no approved medical indications. While there is some animal data and limited human research supporting its potential use case, its safety and efficacy profile is still not well-understood. 

Additionally, AOD 9604 is not on the FDA-approved bulk substance list, and thus is not eligible to be compounded. Any AOD 9604 that is available carries many of the risks associated with unapproved peptide therapy, including potential quality concerns (e.g., mislabeling, purity, etc.). 

Potential Risks and Side Effects 

The FDA states that compounded drugs containing AOD-9604 carry a significant risk for immunogenicity. Additionally, there is a risk of peptide-related impurities and API characterization as the drug is not regulated by the FDA. 

Practical Takeaways  

There is some limited evidence supporting AOD 9604’s impact on lipid metabolism, suggesting its potential to induce weight loss, specifically in animal models. However, it’s risk-benefit profile is still unclear at this stage, which is why it is not approved by the FDA. 

Bottom Line Medical & Regulatory Disclaimer 

The information provided in this article is for educational purposes only and is not intended as medical advice. Many peptides are not FDA-approved for human use outside of limited clinical contexts. These compounds are often obtained through unregulated sources that lack quality control. Studies suggest 30–65% of products may be contaminated or mislabeled, with risks including endotoxins, heavy metals, and incorrect sequences. At Weight Loss & Vitality, we focus on evidence-based, medically supervised therapies. 

As of April 21, 2026, regulatory status for many peptides remains under review and may change as additional data and guidance become available. 

 Learn more about growth hormone peptides, metabolic optimization, and medically supervised wellness therapies offered at Weight Loss & Vitality by visiting our Growth Hormone Peptides service page.

References 

1. https://pubchem.ncbi.nlm.nih.gov/compound/Aod-9604 

1. https://jofem.org/index.php/jofem/article/view/213/278 

1. https://pubmed.ncbi.nlm.nih.gov/11146367/ 

1. https://pubmed.ncbi.nlm.nih.gov/11673763/ 

Author

David J. Bauder, PA-C David Bauder, PA-C, is a certified physician assistant and the assistant medical director at Weight Loss and Vitality in Manassas and Alexandria, Virginia, Washington, DC; and Gaithersburg, MD. He enjoys helping patients optimize their physical and mental health to improve their overall well-being. He earned his physician assistant degree from the University of Texas Health Science Center at San Antonio. Afterward, he gained admission into the reputable graduate program for physician assistant studies at the University of Nebraska Health Science Center in Omaha. David has over 26 years of experience working as a physician assistant. He’s practiced in podiatry, family medicine, emergency medicine, general surgery, urgent care, and functional medicine.